GLOBAL MEDICAL SOLUTIONS SOUTHERN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer

Phase 1

Recruiting

Conditions: Gastric Cancer
Colorectal Cancer
Esophageal Cancer
Sarcoma
Metastatic Sarcoma
Pancreatic Cancer

Interventions: Combination Product: 64Cu-LNTH-1363S

First Posted Date: 2024-03-07

Last Posted Date: 2024-12-12

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 32

Registration Number: NCT06298916

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

PYLARIFY® PET/CT or PET/MRI in Men with Favorable Intermediate Risk (FIR) Prostate Cancer

Phase 4

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Piflufolastat F 18 Intravenous Solution [PYLARIFY]

First Posted Date: 2023-10-10

Last Posted Date: 2025-01-06

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 274

Registration Number: NCT06074510

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Iowa Health Care, Iowa City, Iowa, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

and more 11 locations

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions: Castration-Resistant Prostatic Cancer

First Posted Date: 2023-09-13

Last Posted Date: 2024-12-06

Lead Sponsor: Lantheus Medical Imaging

Registration Number: NCT06033001

Locations: 🇺🇸
Comprehensive Hematology Oncology, Trinity, Florida, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford, Connecticut, United States

and more 4 locations

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Phase 3

Completed

Conditions: Cardiac Disease

Interventions: Drug: DEFINITY®

First Posted Date: 2018-10-25

Last Posted Date: 2021-01-28

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 160

Registration Number: NCT03719612

Locations: 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸
University of California-Irvine, Orange, California, United States

and more 12 locations

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Phase 3

Completed

Conditions: Cardiac Disease

Interventions: Drug: DEFINITY

First Posted Date: 2018-06-27

Last Posted Date: 2020-12-17

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 153

Registration Number: NCT03571672

Locations: 🇺🇸
Alfieri Cardiology, Wilmington, Delaware, United States
🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

and more 6 locations

Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI

Phase 3

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Flurpiridaz F18

First Posted Date: 2012-09-10

Last Posted Date: 2013-05-30

Lead Sponsor: Lantheus Medical Imaging

Registration Number: NCT01681524

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Flurpiridaz F18
Drug: 99mTechnicium (sestamibi or tetrofosmin)

First Posted Date: 2011-05-04

Last Posted Date: 2020-11-24

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 795

Registration Number: NCT01347710

Locations: 🇺🇸
Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana, United States
🇺🇸
Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States
🇺🇸
Saint Louis University School of Medicine, Saint Louis, Missouri, United States

and more 78 locations

Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®

Completed

Conditions: Cardiovascular Disease

First Posted Date: 2011-02-18

Last Posted Date: 2020-11-10

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 4300000

Registration Number: NCT01299649

Locations: 🇺🇸
Lantheus Medical Imaging, N. Billerica, Massachusetts, United States

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

Completed

Conditions: Nephrogenic Systemic Fibrosis

First Posted Date: 2010-06-02

Last Posted Date: 2014-05-07

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 2

Registration Number: NCT01135316

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

Withdrawn

Conditions: Coronary Artery Disease (CAD)

First Posted Date: 2010-03-11

Last Posted Date: 2013-04-04

Lead Sponsor: Lantheus Medical Imaging

Registration Number: NCT01085162

Locations: 🇺🇸
Cedars-Sinai Medical Center, S. Mark Taper Foundation Imaging Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy